Topics:

Rheumatology Network

Five Reasons Your Patients Should Join Arthritis Power

A new symptom-tracking app isn't merely about helping your patients. It's about helping them help everyone with their condition by sharing their experience in a systematic way. Founder Jeffrey Curtis MD describes the new registry and its goals.

Recent Content

osteoporosis

(CCR 2015) A number of new osteoporosis treatments are on the near horizon, drawing on a new understanding of bone biology, as described by a speaker at the Clinical Congress of Rheumatology.

rheumatoid arthritis

(CCR 2015) A new rheumatoid arthritis (RA) research center in the UK intends to revolutionize the understanding and treatment of the rheumatoid arthritis by 2020 by using systems biology to move beyond the one-molecule paradigm.

rheumatoid arthritis

One very targeted clue to treatment failure: An observational study from Israel identifies Sephardic Jews as more likely than Ashkenazim to form antibodies against the biologic drug infliximab.

rheumatoid arthritis

In the second installment of a slide show based on an animated discussion by members of the rheumatology journal club (#rheumjc), partipants focus on the benefits, risks, and realities of tapering biologics in clinical practice.

rheumatoid arthritis

Slides present key points from a Twitter-based journal club, pondering a randomized study of tapering TNF inhibitors in rheumatoid arthritis. Many questions about the study design. More ask about practices already in use (addressed in Part 2).

The biologic adalimumab improves pain and physical function in a randomized trial of patients with peripheral spondyloarthritis unable to take non-steroidal anti-inflammatory drugs.

A meta-analysis involving more than 40,000 patients finds that biologics have a 30% increased infection risk compared to DMARDs, which is greatest for patients who have also used methotrexate.

By clicking Accept, you agree to become a member of the UBM Medica Community.